Cidara buys back rights to flu therapy from J&J for $85m
Share this article Cidara also closed a private placement of preferred stock worth $240m to buy back the rights for CD388 and advance its development.
Share this article Cidara also closed a private placement of preferred stock worth $240m to buy back the rights for CD388 and advance its development.
Share this article The panel at the BioTrinity conference discussed what impact the Inflation Reduction Act will have on life sciences companies. Credit: Jenna Philpott/GlobalData.
Andrew Bowman, a veterinary epidemiologist at Ohio State University, had a hunch. He had been struck by the huge amounts of H5N1 virus he’d seen
Funding represents the first time the foundation has taken an equity position in a breath diagnostics company.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Here in
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in
The association between reproduction and biological aging based on epigenetic clocks.
Mary Bacaj, Ph.D., President of Value-Based Care at Conifer Health Solutions Employers incur approximately $575 billion each year due to their employees’ poor health, and
Rise and shine, everyone, another busy day is on the way. We can tell because countless birds are chirping outside our window, the pace of
Share this article Welcome to the first of five episodes in our podcast series “Digital Deals in Life Sciences – What Makes Them Different?” Transactions